Median survival time than those in the vaccine group was 26 months versus 15 months for the control group. Progression-free survival was 14.2 months in the vaccine group compared with 6.3 months in the control groupOur study showed that the vaccine eliminates all cancer cells with this marker in all but one of the participants in our study, the lead author of the study by Dr. D.
The vaccine puts out a growth factor associated with the most aggressive form of brain cancer.
An old Indian spice and a dye whose cousin is blue to link sports drinks scientists better treatment of traumatic brain injury.
Approximately 10,000 new cases of glioblastoma appear in the U.S. each year.
Approximately one third of all glioblastomas are powered by a very aggressive cancer gene, called EGFRvIII, these tumors are the worst of the worst, Dr. John Sampson, a professor of neurosurgery at Duke University Medical Center, said in a statement again .
The vaccine appears to stimulate an immune response in about half of patients who have received suggests these responses were associated with increased survival time, but the numbers are so small that we can not conclude this with any degree of certainty, Dr. Amy Heimberger, co-principal investigator of the MD Anderson, said in a press release from Duke.
Researchers at Duke University Medical Center and the University of Texas MD Anderson Cancer Center report that the case-control study included 35 patients with newly diagnosed brain cancer known as glioblastoma .
Patients were divided into two groups: surgery received radiation therapy and chemotherapy drug temozolomide, but a group of 18 patients also began receiving injections of the new vaccine one month after completion of radiation and continued to receive the vaccine until it seemed to work.